Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis
Küçük Resim Yok
Tarih
2019
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Sage Publications Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
Açıklama
Anahtar Kelimeler
Abiraterone, Metastatic Castration-Resistant Prostate Cancer, Hemodialysis
Kaynak
Journal Of Oncology Pharmacy Practice
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
25
Sayı
8
